AC Immune (NASDAQ:ACIU) Earns "Buy" Rating from BTIG Research

Key Points

• BTIG Research reaffirmed a “Buy” rating on AC Immune and set an $8.00 price target, implying 222.71% potential upside from the stock’s $2.48 price.
• Analyst sentiment is mixed: three analysts rate the stock Buy, one rates it Hold and one rates it Sell, resulting in a consensus “Hold” rating and an average price target of $7.50.
• AC Immune exceeded quarterly expectations, reporting $0.03 earnings per share versus a consensus loss estimate of $0.10 and revenue of $18.67 million versus $9.59 million expected, though it continues to post substantial net losses.

AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research's target price would suggest a potential upside of 222.71% from the company's current price.

A number of other analysts have also recently weighed in on the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of AC Immune in a research report on Wednesday, August 5th. HC Wainwright reissued a "buy" rating on shares of AC Immune in a research report on Wednesday, July 1st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $7.50.

AC Immune Price Performance

Shares of ACIU traded down $0.10 during trading hours on Thursday, reaching $2.48. 54,844 shares of the company traded hands, compared to its average volume of 287,669. The stock has a market capitalization of $252.29 million, a PE ratio of -4.60 and a beta of 1.59. The stock has a fifty day simple moving average of $2.40 and a 200 day simple moving average of $2.71. AC Immune has a fifty-two week low of $2.03 and a fifty-two week high of $4.00. The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The firm had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. As a group, research analysts predict that AC Immune will post -0.6 EPS for the current fiscal year.

Institutional Trading of AC Immune

Several institutional investors and hedge funds have recently bought and sold shares of ACIU. EFG International AG acquired a new stake in AC Immune in the fourth quarter valued at $41,000. Private Advisor Group LLC bought a new stake in shares of AC Immune during the 3rd quarter worth about $48,000. Sei Investments Co. bought a new position in AC Immune in the 2nd quarter valued at about $51,000. Goldman Sachs Group Inc. lifted its position in AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company's stock worth $58,000 after acquiring an additional 5,920 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new position in shares of AC Immune in the third quarter valued at approximately $63,000. Institutional investors own 51.36% of the company's stock.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source